Evidence map›Paper›PMID 25029232›Full record

ArticleBone marrow transplantation2014

Outcome of patients with HTLV-1-associated adult T-cell leukemia/lymphoma after SCT: a retrospective study by the EBMT LWP.

A Bazarbachi, K Cwynarski, A Boumendil, H Finel, P Fields, K Raj, A Nagler, M Mohty, A Sureda, P Dreger and 1 more

Abstract read
PubMed Publisher
In one paragraph

Article in Bone marrow transplantation, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 44 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
44citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

44 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Revised Adult T-Cell Leukemia-Lymphoma International Consensus Meeting Report.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2019
    Guideline
  2. Trial
  3. Trial
  4. Complete Remissions of Adult T-cell Leukemia with Anti-CD25 Recombinant Immunotoxin LMB-2 and Chemotherapy to Block Immunogenicity.Clinical cancer research : an official journal of the American Association for Cancer Research · 2016
    Trial
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Review
  11. Article
  12. Article
  13. Review
  14. Article
  15. Review
  16. Review
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

A BazarbachiMedical Center, Department of Internal Medicine, American University of Beirut, Beirut, Lebanon.
K CwynarskiDepartment of Haematology, Royal Free Hospital, London, UK.
A BoumendilLWEBMT Paris Office, Hôpital Saint-Antoine, Paris, France.
H FinelLWEBMT Paris Office, Hôpital Saint-Antoine, Paris, France.
P FieldsDepartment of Haematology, Guys and St Thomas' and Kings College Hospitals, London, UK.
K RajDepartment of Haematology, Guys and St Thomas' and Kings College Hospitals, London, UK.
A NaglerChaim Sheba Medical Center, Tel Aviv University, Tel-Hashomer, Israel.
M Mohty1] Service d'Hématologie clinique et Thérapie Cellulaire, Hôpital Saint-Antoine, Paris, France [2] Universite Pierre & Marie Curie, Paris, France.
A SuredaHaematology Department, Addenbrookes Hospital, Cambridge University, Cambridge, UK.
P DregerDepartment of Medicine V, University of Heidelberg, Heidelberg, Germany.
O Hermine1] Department of Hematology, Hôpital Necker, University of Paris, Paris, France [2] Imagine Institute, INSERM U1163 CNRS ERL 8254, Paris, France.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Adult T-cell leukemia/lymphoma (ATL) carries a dismal prognosis. Experience with allo-SCT for ATL appears encouraging but is limited to Japanese series. This retrospective analysis of the EBMT registry revealed 21 HTLV-I seropositive ATL including 7 acute and 12 lymphoma subtypes. Four patients received auto-SCT and rapidly died from ATL. Out of 17 allo-SCT (4 myeloablative, 13 reduced intensity), 6 are still alive (4 were in CR1 at SCT). Eleven patients died within 2 years, eight from relapse/progression and three from transplant toxicity. Six of seven informative patients who lived >12 months had chronic GVHD. Overall these results indicate that allo-SCT but not auto-SCT may salvage a subset of ATL patients, supporting the existence of graft vs ATL effect also in non-Japanese patients.

Indexed as

AdultAgedDisease ProgressionFemaleHumansHuman T-lymphotropic virus 1Leukemia-Lymphoma, Adult T-CellMaleMiddle AgedPrognosisRetrospective StudiesTreatment Outcome

Identifiers

PMID25029232

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.